Medical News Brief | Guangdong Launches Medical Equipment Leasing Pilot; Philips Issues Class I Recall of Panorama HFO MRI System

1. Guangdong Launches Pilot Program for Medical Equipment Leasing

Recently, the General Office of the People's Government of Guangdong Province issued a notice on the pilot work plan for equipment leasing in the fields of education, science and technology, and health care in Guangdong Province. The "Work Plan for the Pilot Program of Equipment Leasing in the Health Care Sector of Our Province" proposed to implement the specific deployment of the "1310" plan by the Provincial Party Committee, with the aim of creating a demonstration province for high-quality development in health care. This initiative will be linked to the five-year action plan to improve grassroots health care service capabilities as part of the "High-Quality Development Project for Hundreds of Counties, Thousands of Towns, and Tens of Thousands of Villages." It seeks to optimize the use of fiscal funds, fully utilizing Guangdong’s strong manufacturing base and large procurement volume of medical equipment. The program aims to carry out medical equipment leasing within the health care sector to reduce operational costs for health care institutions, enhance operational efficiency, and further stimulate the enthusiasm of these institutions—especially those currently acquiring medical equipment through government funding—to participate in leasing. This effort will continuously promote the expansion and enhancement of high-quality medical resources, ensuring their balanced regional distribution. It also aims to effectively guarantee the provision of essential public health services in the health care sector, meeting the growing demand of the population for high-quality and efficient health care, thereby better serving the high-quality economic and social development in China. (Xiaoju Deng Network)

2. Single-use Intracardiac Ultrasound Diagnostic Catheter Approved for Marketing

Recently, the National Medical Products Administration approved the registration application for the innovative product "Single-Use Intracardiac Echocardiography Diagnostic Catheter" produced by Jiangsu TINGSN Technology Co., Ltd. The product consists of a catheter body, an operating handle, and a connector. When used with the company's portable color ultrasound diagnostic system, it is suitable for medical institutions to perform ultrasound imaging of the heart, major cardiac vessels, and intracardiac anatomical structures. Utilizing high-frequency ultrasound, the product generates two-dimensional images and three-dimensional models of the heart area, enabling accurate, rapid, and efficient ultrasound-guided surgeries. It provides real-time, precise anatomical images while monitoring hemodynamic changes, offering clear visualization of cardiac tissue characteristics and fine structures. Additionally, it allows for real-time monitoring, promptly detects surgery-related complications, and maximizes surgical safety. The product’s market entry will help reduce clinical treatment costs, benefiting more patients. (National Medical Products Administration)

3. Philips Voluntarily Recalls Medical Magnetic Resonance Imaging Systems

Philips (China) Investment Co., Ltd. reported that due to potential issues such as unexpected excessive helium pressure during magnet quench and structural integrity failure of the Panorama HFO system components, Philips Medical Systems Nederland B.V. Business Unit Magnetic Resonance-site Best initiated a voluntary recall of its medical magnetic resonance imaging systems (Registration No.: SFDA (Import) 2012 No. 3282359). The recall is classified as Class I. (National Medical Products Administration)

4. "World's First" Compliance Digital Product - "Compliance Connect"

Since the full implementation of the medical device GMP in 2018, the increasingly stringent regulation of medical devices has led to the normalization of spot checks, unannounced inspections, and information disclosure. To assist medical device companies in addressing risks during the compliance process and achieving compliance goals, Orthogonal, a globally leading medical device industry service provider and regional medical device industry operator, has independently developed and launched "the world's first" compliance digital product — "Compliance Express," offering enterprises one-stop compliance solutions throughout the entire life cycle of medical devices. This drives the progress of corporate compliance matters and enhances the efficiency of compliance work. (Compiled by Orthogonal)

5. Musk's Brain-Computer Interface Company Completes $320 Million in New Financing, Valuation Exceeds 35 Billion Yuan!

Recently, Neuralink, an invasive brain-computer interface company founded by Elon Musk, has completed a new round of financing totaling $320 million (approximately 2.309 billion yuan). To date, Neuralink's total financing is close to $500 million. As early as June this year, Reuters reported that Neuralink's valuation had exceeded $5 billion (approximately 35.717 billion yuan). It is reported that Neuralink was established in 2016 by Elon Musk. The company is dedicated to the research of brain-computer interface technology and is developing a brain implant that uses invasive brain-computer interface technology to implant tiny electrodes into the brain. By using electrical currents, it aims to create "interaction" between computers and brain cells, with the hope of helping paralyzed individuals walk again and curing other neurological disorders. (TMT Post)

6. Artificial Intelligence Helps Increase Early Screening Rate of Pancreatic Cancer

Pancreatic cancer, known as the "king of cancers," has the lowest five-year survival rate among all malignant tumors. It is very difficult to detect pancreatic cancer using common non-contrast CT scans. However, with the assistance of artificial intelligence (AI), non-contrast CT scans have the potential to be used for large-scale early screening of pancreatic cancer. Led by the Shanghai Pancreatic Disease Research Institute, a research team in collaboration with Alibaba's DAMO Academy, the First Affiliated Hospital of Zhejiang University School of Medicine, and other institutions, developed a unique deep learning framework, which was ultimately trained into the pancreatic cancer detection model (PANDA). This research fully demonstrates that utilizing 'non-contrast CT + AI' for large-scale early screening of pancreatic cancer holds great potential. It will provide new support for optimizing clinical guidelines for pancreatic cancer screening and will positively impact future diagnostic and treatment processes, treatment decisions, and treatment costs for pancreatic tumors. (Science and Technology Daily)

7. The First Multi-chamber Cardiac Organoid Model Unveiled, Advancing Research on Human Heart Development and Diseases

Recently, a research team from the Institute of Molecular Biotechnology (IMBA) of the Austrian Academy of Sciences has developed the first physiological organoid model, which includes all major cardiac developmental structures, enabling scientists to advance drug development and toxicology research. The research findings were published in the journal *Cell* on the 28th. In the future, this multi-chamber heart organoid could also be used for toxicology studies and the development of new drugs with chamber-specific effects. Additionally, heart organoids derived from patient stem cells will further aid in understanding, treating, and preventing developmental defects. (China Economic Net)